Posted by Michael Wonder on 02 May 2023
Minerva Neurosciences announces the NDA filing for roluperidone for the treatment of negative symptoms in schizophrenia
1 May 2023 - FDA grants appeal and files NDA.
Minerva Neurosciences today announced that the US FDA filed the Company’s new drug application for roluperidone for the treatment of negative symptoms in patients with schizophrenia on 27 April 2023.
